Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2015-06, Vol.15 (1), p.483-483, Article 483
Main Authors: Forse, Catherine L, Agarwal, Seema, Pinnaduwage, Dushanthi, Gertler, Frank, Condeelis, John S, Lin, Juan, Xue, Xiaonan, Johung, Kimberly, Mulligan, Anna Marie, Rohan, Thomas E, Bull, Shelley B, Andrulis, Irene L
Format: Article
Language:English
Subjects:
Aged
Analysis
Biomarkers, Tumor - biosynthesis
Biomarkers, Tumor - genetics
Breast cancer
Breast Neoplasms - genetics
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cancer
Chemotherapy
Diagnosis
Female
Gene Expression Regulation, Neoplastic
Health aspects
Humans
Kaplan-Meier Estimate
Metastasis
Methods
Microfilament Proteins - biosynthesis
Microfilament Proteins - genetics
Middle Aged
Neoplasm Metastasis
Prognosis
Protein Isoforms - biosynthesis
Protein Isoforms - genetics
Receptor, ErbB-2 - genetics
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Analysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features. High Menacalc was associated with increased risk of death from any cause (P=0.0199, HR (CI)=2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n=142) (P=0.0052, HR (CI)=3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-015-1468-6